France Hemato Oncology Testing Market Size & Outlook

The hemato oncology testing market in France is expected to reach a projected revenue of US$ 291.0 million by 2028. A compound annual growth rate of 13.8% is expected of France hemato oncology testing market from 2021 to 2028.
Revenue, 2020 (US$M)
$103.4
Forecast, 2028 (US$M)
$291.0
CAGR, 2021 - 2028
13.8%
Report Coverage
France

France hemato oncology testing market highlights

  • The France hemato oncology testing market generated a revenue of USD 103.4 million in 2020 and is expected to reach USD 291.0 million by 2028.
  • The France market is expected to grow at a CAGR of 13.8% from 2021 to 2028.
  • In terms of segment, lymphoma was the largest revenue generating cancer type in 2020.
  • Lymphoma is the most lucrative cancer type segment registering the fastest growth during the forecast period.


Hemato oncology testing market data book summary

Market revenue in 2020USD 103.4 million
Market revenue in 2028USD 291.0 million
Growth rate13.8% (CAGR from 2020 to 2028)
Largest segmentLymphoma
Fastest growing segmentLymphoma
Historical data2018 - 2019
Base year2020
Forecast period2021 - 2028
Quantitative unitsRevenue in USD million
Market segmentationLeukemia, Lymphoma, MPNs, Other Cancers
Key market players worldwideRoche Holding AG, Abbott Laboratories, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Bio-Techne Corp


Other key industry trends

  • In terms of revenue, France accounted for 4.4% of the global hemato oncology testing market in 2020.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
  • In Europe, Germany hemato oncology testing market is projected to lead the regional market in terms of revenue in 2028.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 382.6 million by 2028.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Hemato Oncology Testing Market Companies

Name Profile # Employees HQ Website

France hemato oncology testing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemato oncology testing market will help companies and investors design strategic landscapes.


Lymphoma was the largest segment with a revenue share of 45.94% in 2020. Horizon Databook has segmented the France hemato oncology testing market based on leukemia, lymphoma, mpns, other cancers covering the revenue growth of each sub-segment from 2018 to 2028.


France is expected to exhibit lucrative growth during the forecast period owing to high incidence of blood cancers, local presence of major market players, and growing awareness about early diagnosis & treatment of blood cancer.

According to data published by Globocan in 2020, around 11,720 new cases of leukemia, 14,446 new cases of non-Hodgkin lymphoma were diagnosed in France. According to same source, around 6,907, 5 859, and 257 patients died due to leukemia, non-Hodgkin lymphoma, and Hodgkin lymphoma, respectively, in France.

Such high incidence and mortality rate has driven the demand for advance testing solutions and supported the market growth.

Reasons to subscribe to France hemato oncology testing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of France hemato oncology testing market databook

  • Our clientele includes a mix of hemato oncology testing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the France hemato oncology testing market , including forecasts for subscribers. This country databook contains high-level insights into France hemato oncology testing market from 2018 to 2028, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

France hemato oncology testing market size, by cancer type, 2018-2028 (US$M)

France Hemato Oncology Testing Market Outlook Share, 2020 & 2028 (US$M)

France hemato oncology testing market size, by cancer type, 2018-2028 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more